Roche's Tecentriq and Avastin combination decreases risk of disease worsening or death in Phase III cancer study
8 February 2018 -

Roche, a Swiss multinational healthcare company, has stated that the combination of Tecentriq (atezolizumab) and Avastin (bevacizumab) decreased the risk of disease worsening or death compared to patients treated with sunitinib by 26% in certain people with advanced kidney cancer in a Phase III study, it was reported yesterday.

The trial is named IMmotion151 and has met its co-primary endpoint of progression-free survival in patients whose metastatic renal cell carcinoma expressed the PD-L1 protein. In the study, the Roche immuno-oncology combination was assessed against Pfizer's sunitinib, which was approved by the US Food and Drug Administration (FDA) for the treatment of kidney cancer. The global trial included 915 people having locally advanced or metastatic renal cell carcinoma that was inoperable, and could not undergo prior systemic active or experimental therapy.

The company stated that preliminary observations from the co-primary endpoint of overall survival in the entire patient population were promising, but are still immature.